Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation

Medexus Confirms Cash Flow Accretion as GRAFAPEX Commercialization Accelerates

By The Northwire Desk — AI Analysis Apr 15, 2026 · 17:31 MDP · 4.03 MEDEXUS PHARMACEUTICALS INC. J
Executive Summary
  • Medexus Pharmaceuticals provided an operational update on the US commercialization of GRAFAPEX (treosulfan) for Injection, reporting growth in formulary inclusions and product orders at transplant centers.
  • Formulary inclusions increased to 56 institutions (31% of 180 US transplant centers), up from 26% as of December 31, 2025.
  • Product orders reached 64 of the 180 US transplant centers, up from 55 as of December 31, 2025.
  • Management reaffirmed expectations that annual product-level net revenue from GRAFAPEX will exceed $100 million within five years of its commercial launch.
  • The company expects GRAFAPEX to be accretive to quarterly operating cash flows starting in fiscal Q4 2026 (calendar Q1 2026), confirming previous guidance.
  • Capital structure simplification was completed: repurchased 710,100 shares under NCIB for C$2.1 million and all outstanding warrants from the October 2023 offering expired or were exercised.
  • No warrants to purchase common shares remain outstanding as of April 6, 2026.
Material Impact
  • The news confirms previously disclosed expectations regarding cash flow accretion timing (FY26 Q4/Calendar Q1 2026) rather than introducing a surprise acceleration or delay.
  • Commercial progress (formulary and orders) is incremental but positive, showing steady adoption without indicating a sudden spike in demand that would materially alter revenue models immediately.
  • The removal of all outstanding warrants eliminates future dilution risk from the October 2023 offering, which is a structural improvement but was anticipated given the expiration date.
  • Share repurchases ($1.5M USD / C$2.1M CAD) are modest relative to the company's cash position and do not represent a major capital allocation shift compared to the credit facility announced in November 2025.
  • The market reaction (price rising from ~$3.12 on March 31 to $4.06 by April 14) suggests expectations were already priced in prior to this release, making the news routine confirmation rather than a catalyst for new valuation expansion.
MDP · Price
Company Overview
  • Company: Medexus Pharmaceuticals Inc., a commercial-stage pharmaceutical company focused on oncology and transplant medicine.
  • Flagship Project: GRAFAPEX (treosulfan) for Injection, launched in the US in February 2025. It is indicated for conditioning regimens prior to hematopoietic stem cell transplantation.
  • Development Status: Commercialization phase in the US; seeking formulary inclusion at transplant centers.
  • Other Products: Rupall (Canada), Rasuvo, IXINITY, Trecondyv. Rupall faces generic erosion; GRAFAPEX is the primary growth driver.
Read the original news release →

More from MEDEXUS PHARMACEUTICALS INC. J

Jun 25, 2026 · 18:01

GRAFAPEX execution on plan, but +44% run into print prices in the optimism; legacy erosion offsets top-line growth.

Earnings Jun 09, 2026 · 17:31

Medexus adds late-stage cell therapy to pipeline, but near-term value remains tethered to GRAFAPEX commercialization ramp

M&A / Property Feb 11, 2026 · 17:31

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Earnings Nov 20, 2025 · 07:31

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Other Nov 17, 2025 · 18:35

Medexus obtains $51-million (U.S.) credit, plans NCIB

Financings Nov 17, 2025 · 08:31

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares

Financings